Welcome to our dedicated page for Bemis news (Ticker: BMS), a resource for investors and traders seeking the latest updates and insights on Bemis stock.
Bemis Co., Inc. (BMS) delivers innovative packaging solutions for food preservation, medical devices, and pharmaceutical products through its U.S. and Global Packaging segments. This news hub provides investors and industry professionals with essential updates about the company's operational developments, financial performance, and technological advancements.
Access timely reports on earnings announcements, material science innovations, and strategic initiatives shaping the packaging industry. Our curated collection includes regulatory compliance updates, sustainability efforts, and market expansion news relevant to BMS's core sectors.
Key focus areas include developments in polymer-based food safety solutions, healthcare packaging certifications, and manufacturing process improvements. Bookmark this page to stay informed about how BMS addresses evolving challenges in product preservation and distribution across global markets.
Bristol Myers Squibb (NYSE: BMY) and Bain Capital have announced the formation of a new independent biopharmaceutical company focused on developing immunology therapies for autoimmune diseases. The new company launches with $300 million in financing led by Bain Capital and five immunology assets in-licensed from BMS.
The portfolio includes three clinical-stage and two Phase 1-ready investigational medicines, with the most advanced being afimetoran, a TLR7/8 inhibitor in Phase 2 trials for lupus, and BMS-986322, a TYK2 inhibitor that showed positive Phase 2 results in plaque psoriasis. BMS will maintain a 20% equity stake in the new company and receive royalties and milestones tied to asset success.
Daniel S. Lynch will serve as Executive Chairman and interim CEO, with representatives from both BMS and Bain Capital joining the board of directors.
K36 Therapeutics announced multiple poster presentations at the 66th American Society of Hematology (ASH) Annual Meeting, highlighting the first clinical data for their MMSET/NSD2 inhibitors, KTX-1001 and KTX-1029. The presentations will cover the dose escalation part of KTX-1001's Phase 1 study, showing increased exposure and decreased H3K36me2 biomarker, indicating clear target engagement. KTX-1029, a potent and selective MMSET inhibitor, demonstrated efficacy in preclinical models. Together, these data support the rationale for targeting MMSET in multiple myeloma. The favorable tolerability profile of KTX-1001 and promising clinical activity suggest its potential as a first-in-class therapy for t(4;14) multiple myeloma patients.
AVEO Oncology reported Q3 2021 revenue of $15.2 million, significantly up from $3.6 million in Q3 2020, driven largely by FOTIVDA® sales of $14.3 million. The company saw a 113% increase in quarterly revenue from the previous quarter, bolstered by the growing demand for FOTIVDA in treating relapsed/refractory renal cell carcinoma. Enrollment for the Phase 3 TiNivo-2 trial of tivozanib in combination with OPDIVO® has begun. Additionally, ficlatuzumab received Fast Track Designation from the FDA. AVEO ended the quarter with $94 million in cash and anticipates maintaining operations for at least 12 months.
